All articles tagged with #mesothelioma
A Baltimore jury awarded over $1.5 billion to Cherie Craft, who claimed J&J's talc products caused her asbestos-related cancer, and J&J plans to appeal, citing the verdict as egregious and unconstitutional. The case adds to thousands of lawsuits against J&J over talc-related health claims, which the company denies, asserting its products are safe.
A Minnesota jury awarded $65.5 million to a woman who claimed Johnson & Johnson's talcum powder exposed her to asbestos and contributed to her developing mesothelioma, part of ongoing legal battles over the safety of talc products.
A Minnesota jury awarded $65.5 million to a woman who claimed Johnson & Johnson's talcum powder, contaminated with asbestos, caused her mesothelioma, highlighting ongoing legal battles over the safety of talc products.
A Minnesota jury awarded $65.5 million to a woman who claimed Johnson & Johnson's talcum products caused her asbestos-related cancer, marking a significant legal victory amid ongoing lawsuits alleging health risks from talc. Johnson & Johnson plans to appeal the verdict, which is part of a broader legal battle over the safety of their talc products.
A Los Angeles jury ordered Johnson & Johnson to pay $966 million to the family of a woman who died from mesothelioma, due to allegations that its talc products contained asbestos fibers. J&J plans to appeal, denying the claims and asserting the products are safe. The case is part of a larger wave of lawsuits against J&J related to talc and cancer.
A California jury ordered Johnson & Johnson to pay a record $966 million in damages to the family of Mae Moore, who blamed her mesothelioma on lifelong use of the company's talc baby powder, marking the largest verdict in a 15-year legal battle over the product's alleged health risks. J&J plans to appeal the decision.
A Los Angeles jury ordered Johnson & Johnson to pay $966 million in damages after finding the company liable in a lawsuit where its talc baby powder was alleged to contain asbestos fibers causing mesothelioma in Mae Moore, who died in 2021. The verdict includes $16 million in compensatory damages and $950 million in punitive damages, though it may be reduced on appeal.
A Beaverton woman, Kyung Lee, was awarded $260 million by a Portland jury after claiming Johnson & Johnson's talc-based Baby Powder caused her mesothelioma. The jury found the company directly responsible due to asbestos in the product. Johnson & Johnson plans to appeal the decision, asserting the safety of their talc products.
A new drug called pegargiminase has shown promise in a phase 3 clinical trial for treating pleural mesothelioma, a deadly cancer caused by exposure to asbestos. Patients who received the drug alongside conventional chemotherapy were four times as likely to be alive after three years compared to those who received a placebo. The drug works by degrading an amino acid called arginine, which many mesothelioma cells lack the ability to produce, leading to their struggle to function. The drug is also being assessed in clinical trials for other types of cancer.
Researchers at Queen Mary University London have developed a new drug, ADI-PEG20, that shows promise in treating mesothelioma, an aggressive form of cancer often caused by asbestos exposure. The drug, when combined with chemotherapy, increased median overall survival by 1.6 months and quadrupled survival at 36 months compared to a placebo. This marks the first successful combination with chemotherapy in 20 years and offers hope for patients with this challenging cancer.
Researchers at Queen Mary University of London have developed a new drug, ADI-PEG20, which has shown promising results in treating mesothelioma, a hard-to-treat and aggressive form of cancer linked to asbestos exposure. The drug, which works by cutting off the tumor's food supply, has quadrupled three-year survival rates and increased average survival by 1.6 months. The study, published in JAMA Oncology, involved 249 patients and found that those who received the new drug alongside chemotherapy survived for an average of 9.3 months, compared to 7.7 months for those who had a placebo and chemotherapy. This breakthrough offers hope to patients with mesothelioma and represents the first successful combination of chemotherapy with a drug that targets cancer's metabolism developed for this disease in 20 years.
Scientists at Queen Mary University in the UK have developed a new drug, ADI-PEG20, which has shown promising results in treating mesothelioma, a deadly cancer caused by asbestos exposure. The drug, which works by cutting off the tumor's food supply, has quadrupled three-year survival rates and increased average survival by 1.6 months. This breakthrough marks the first successful combination of chemotherapy with a drug that targets cancer's metabolism for this disease in 20 years, offering hope for improved treatment outcomes for mesothelioma patients.
Researchers at Queen Mary University of London have developed a new drug, ADI-PEG20, that has shown promising results in treating mesothelioma, a hard-to-treat cancer. The drug, used in combination with chemotherapy, has quadrupled three-year survival rates and increased average survival by 1.6 months in patients. The study, sponsored by Polaris Pharmaceuticals and funded by Cancer Research UK, has been hailed as a significant breakthrough in cancer treatment, offering hope to those affected by mesothelioma.
Scientists at Queen Mary University of London have developed a new drug, ADI-PEG20, which has shown promising results in treating mesothelioma, a hard-to-treat and aggressive form of cancer. The drug, which works by cutting off the tumor's food supply, has quadrupled three-year survival rates and increased average survival by 1.6 months. This breakthrough marks the first successful combination of chemotherapy with a drug that targets cancer's metabolism for this disease in 20 years, offering hope to patients and the medical community.
Scientists have developed a new drug, ADI-PEG20, to treat mesothelioma, a cancer linked to asbestos exposure, in a major breakthrough after two decades. The drug, which cuts off the tumor's food supply, quadrupled three-year survival rates in an international trial involving patients from five countries. The study, published in JAMA Oncology, showed that the new drug, combined with chemotherapy, increased median overall survival by 1.6 months and significantly improved long-term survival compared to a placebo. The breakthrough offers fresh hope to those with mesothelioma and their families, and is a significant advancement in the treatment of this aggressive and deadly cancer.